U.S. Markets close in 1 hr 16 mins

Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review

NEW YORK, NY / ACCESSWIRE / October 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Acasti Pharma Inc. (ACST), a biopharmaceutical company advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population.

On August 14, 2018, the company's shares were trading at $.45 per share. Since then the ACST shares have hit a high of $1.80 before settling at today's level of $1.19.

Milestones, full pipeline review and analysts price target here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/acasti-pharma/

On October 4th, 2018, the company announced that, in connection with its overnight marketed public offering previously announced on October 3, 2018, it has entered into an underwriting agreement with Mackie Research Capital Corporation to sell 18,750,000 Class A Shares at a price of C$1.28 per Common Share, for aggregate gross proceeds to Acasti of C$24,000,000.

On October 4, 2018, the Company also priced a separate and concurrent underwritten public offering of Common Shares in the United States at a price of US$1.00 for total gross proceeds of US$16,600,000.

Recent events and analyst targets in this comprehensive review READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/acasti-pharma/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source



View source version on accesswire.com:
https://www.accesswire.com/513745/Acasti-Pharma-Looks-Toward-Phase-III-for-CaPre-with-Recent-Financing-Analysts-Review



View source version on accesswire.com:
https://www.accesswire.com/513745/Acasti-Pharma-Looks-Toward-Phase-III-for-CaPre-with-Recent-Financing-Analysts-Review